Main Article Content
Metastatic breast cancer patients may acquire oral morbidity from therapeutic procedures. A common adverse event (AE) of the Mammalian target of rapamycin (mTOR) inhibitor is associated stomatitis (mIAS) secondary to mTOR inhibitor therapy, which have a negative impact on the quality of life, therapy adherence and health care expenses. A multidisciplinary team strategy is essential for reducing mIAS and capitalize on therapy advantages for breast cancer patients. We discuss the pathophysiology, diagnosis, and natural history of mIAS in this review. In the context of promoting a coordinated team care approach to optimizing patient care, current and new management policies are outlined for the prevention and treatment of mIAS. Types of Studies Reviewed: We piloted different research from 2007 through 2019 using the terms “stomatitis,” “mIAS,” “mTOR,” “everolimus,” “oral care.” And “metastatic breast cancer,” We have chosen papers from peer-reviewed journals reporting controlled trials and evidence-based guidance. Results: Cytototoxic chemical or radiation therapy causes, clinical presentation, and paradigms of therapy can distinguish mIAS from mucositis. The continuum of patient oral health care may include specific preventive and therapeutic leadership approaches. Practical consequences: Oral health providers are at the forefront of oral health care for patients who have metastatic breast cancer and are uniquely positioned to deliver patient education, to advocate precise reporting of mIAS, and to encourage early identification, monitoring and rapid intervention to reduce the serious and time-limiting dose of this manageable AE.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.